Posted by Michael Wonder on 27 Mar 2025
Soleno Therapeutics announces US FDA approval of Vykat XR to treat hyperphagia in Prader-Willi syndrome
26 March 2025 - First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome.
Soleno Therapeutics today announced that the US FDA has approved Vykat XR (diazoxide choline) extended release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome.
